Centre de Recherchesurl' Inflammation (CRI), Universite Paris Diderot, Paris, Île-de-France, France.
INSERM UMR_S1149, University Paris Cite, Paris, France.
Gut. 2023 Aug;72(8):1581-1591. doi: 10.1136/gutjnl-2022-328708. Epub 2023 Feb 14.
Current prognostic scores of patients with acutely decompensated cirrhosis (AD), particularly those with acute-on-chronic liver failure (ACLF), underestimate the risk of mortality. This is probably because systemic inflammation (SI), the major driver of AD/ACLF, is not reflected in the scores. SI induces metabolic changes, which impair delivery of the necessary energy for the immune reaction. This investigation aimed to identify metabolites associated with short-term (28-day) death and to design metabolomic prognostic models.
Two prospective multicentre large cohorts from Europe for investigating ACLF and development of ACLF, CANONIC (discovery, n=831) and PREDICT (validation, n=851), were explored by untargeted serum metabolomics to identify and validate metabolites which could allow improved prognostic modelling.
Three prognostic metabolites strongly associated with death were selected to build the models. 4-Hydroxy-3-methoxyphenylglycol sulfate is a norepinephrine derivative, which may be derived from the brainstem response to SI. Additionally, galacturonic acid and hexanoylcarnitine are associated with mitochondrial dysfunction. Model 1 included only these three prognostic metabolites and age. Model 2 was built around 4-hydroxy-3-methoxyphenylglycol sulfate, hexanoylcarnitine, bilirubin, international normalised ratio (INR) and age. In the discovery cohort, both models were more accurate in predicting death within 7, 14 and 28 days after admission compared with MELDNa score (C-index: 0.9267, 0.9002 and 0.8424, and 0.9369, 0.9206 and 0.8529, with model 1 and model 2, respectively). Similar results were found in the validation cohort (C-index: 0.940, 0.834 and 0.791, and 0.947, 0.857 and 0.810, with model 1 and model 2, respectively). Also, in ACLF, model 1 and model 2 outperformed MELDNa 7, 14 and 28 days after admission for prediction of mortality.
Models including metabolites (CLIF-C MET) reflecting SI, mitochondrial dysfunction and sympathetic system activation are better predictors of short-term mortality than scores based only on organ dysfunction (eg, MELDNa), especially in patients with ACLF.
目前急性失代偿性肝硬化(AD)患者的预后评分,尤其是伴有慢加急性肝衰竭(ACLF)的患者,低估了死亡率。这可能是因为反映 AD/ACLF 的主要驱动因素——全身炎症(SI)并未反映在评分中。SI 引起代谢变化,从而损害免疫反应所需的能量供应。本研究旨在确定与短期(28 天)死亡相关的代谢物,并设计代谢组学预后模型。
通过非靶向血清代谢组学对来自欧洲的两个前瞻性、多中心的 ACLF 研究和 ACLF 发展队列(CANONIC,发现队列,n=831;PREDICT,验证队列,n=851)进行探索,以确定和验证可用于改善预后模型的代谢物。
选择了 3 种与死亡强烈相关的预后代谢物来构建模型。4-羟基-3-甲氧基苯乙二醇硫酸盐是去甲肾上腺素的衍生物,可能来源于脑干对 SI 的反应。此外,半乳糖醛酸和己酰肉碱与线粒体功能障碍有关。模型 1 仅包含这 3 种预后代谢物和年龄。模型 2 围绕 4-羟基-3-甲氧基苯乙二醇硫酸盐、己酰肉碱、胆红素、国际标准化比值(INR)和年龄构建。在发现队列中,与 MELDNa 评分相比,这两个模型在入院后 7、14 和 28 天内预测死亡的准确性更高(C 指数:0.9267、0.9002 和 0.8424,0.9369、0.9206 和 0.8529,分别对应模型 1 和模型 2)。验证队列也得到了类似的结果(C 指数:0.940、0.834 和 0.791,0.947、0.857 和 0.810,分别对应模型 1 和模型 2)。此外,在 ACLF 中,模型 1 和模型 2 在入院后 7、14 和 28 天预测死亡率方面优于 MELDNa。
包含反映 SI、线粒体功能障碍和交感神经系统激活的代谢物(CLIF-C MET)的模型比仅基于器官功能障碍的评分(如 MELDNa)更好地预测短期死亡率,尤其是在 ACLF 患者中。